Victoza

Victoza. It is a medication belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, used primarily in the management of type 2 diabetes mellitus. Developed by the Danish pharmaceutical company Novo Nordisk, it is administered via subcutaneous injection and functions by mimicking the action of the natural incretin hormone to improve glycemic control. Its approval by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) marked a significant advancement in diabetes therapeutics.

Medical uses

Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is often prescribed when other medications, such as metformin or sulfonylureas, have not provided adequate control of blood glucose levels. Clinical trials, including the landmark LEADER trial, have also demonstrated its cardiovascular benefits, leading to its use in patients with established cardiovascular disease to reduce the risk of major adverse cardiovascular events. It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Adverse effects

The most common adverse effects associated with Victoza involve the gastrointestinal tract, including nausea, vomiting, diarrhea, and constipation, which are often transient. More serious potential risks include the development of medullary thyroid carcinoma, as seen in rodent studies, leading to a black box warning from the FDA; however, a causal link in humans has not been established. There is also a risk of acute pancreatitis, and patients are advised to discontinue use if symptoms such as severe abdominal pain occur. Other warnings pertain to possible acute kidney injury and hypersensitivity reactions, including anaphylaxis.

Pharmacology

Victoza contains the active substance liraglutide, which is an analog of human glucagon-like peptide-1 (GLP-1). It acts as a GLP-1 receptor agonist, binding to and activating GLP-1 receptors on pancreatic beta cells, which stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon release. This mechanism helps lower postprandial glucose and fasting glucose levels. Additionally, it slows gastric emptying, which contributes to increased satiety and potential weight loss. Liraglutide has a prolonged duration of action due to its modification with a fatty acid chain, allowing for binding to albumin and once-daily dosing.

History

Liraglutide was discovered and developed by researchers at Novo Nordisk in Bagsværd, Denmark. The clinical development program, known as the Liraglutide Effect and Action in Diabetes (LEAD) trials, involved thousands of patients across multiple countries. Based on this data, Victoza received its first regulatory approval from the European Medicines Agency in 2009, followed by approval from the U.S. Food and Drug Administration in 2010. The positive cardiovascular outcomes data from the subsequent LEADER trial, published in *The New England Journal of Medicine*, significantly expanded its therapeutic profile and labeling in 2017.

Society and culture

Victoza has had a substantial impact on diabetes care and the pharmaceutical market, becoming a blockbuster drug for Novo Nordisk. Its success contributed to the broader development and popularity of the GLP-1 receptor agonist class, including later agents like semaglutide (marketed as Ozempic). The drug has been the subject of direct-to-consumer advertising campaigns, especially in the United States, and has been featured in medical discussions at conferences like those of the American Diabetes Association. Its high cost has also placed it at the center of debates regarding drug pricing and access within healthcare systems like the National Health Service (NHS) in the United Kingdom.

Category:Antidiabetic drugs Category:Novo Nordisk